Epizyme Reports Second Quarter 2017 Financial Results And Clinical And Business Progress

Published: Aug 04, 2017

CAMBRIDGE, Mass., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today reported operating results for the second quarter 2017 and highlighted recent business and clinical progress.

“Our focus throughout 2017 has been on executing important clinical and regulatory milestones across our tazemetostat program to enable us to bring this first-in-class agent to patients as quickly as we can,” said Robert Bazemore, president and chief executive officer of Epizyme.

Back to news